Home › Mitral Valve Insufficiency › NCT04688190
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * clinically significant mitral insufficiency * patient underwent screening for TMVI * echocardiography data at baseline (and after TMVI, E2E and surgery) * follow-up of at least 30 days Exclusion Criteria: \- age under 18 years
About the study
This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice.
Patients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical/conservative therapy.
Sponsor: Universitätsklinikum Hamburg-Eppendorf · Participants: 1,000 · Started: Nov 1, 2020
Contact the study team
- Sebastian Ludwig, MD · Phone: +494074100
- Lena Strotmann, MD · Phone: +4074100
Official record on ClinicalTrials.gov — NCT04688190
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.